Alpha-Emitting Radionuclides: Current Status and Future Perspectives

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Jan 23

PMID 38256909

Authors

Matthias Miederer

Martina Benesova-Schafer

Constantin Mamat

David Kastner

Marc Pretze

Enrico Michler

Claudia Brogsitter

Jorg Kotzerke

Klaus Kopka

David A Scheinberg

Michael R McDevitt

Affiliations

Soon will be listed here.

Abstract

The use of radionuclides for targeted endoradiotherapy is a rapidly growing field in oncology. In particular, the focus on the biological effects of different radiation qualities is an important factor in understanding and implementing new therapies. Together with the combined approach of imaging and therapy, therapeutic nuclear medicine has recently made great progress. A particular area of research is the use of alpha-emitting radionuclides, which have unique physical properties associated with outstanding advantages, e.g., for single tumor cell targeting. Here, recent results and open questions regarding the production of alpha-emitting isotopes as well as their chemical combination with carrier molecules and clinical experience from compassionate use reports and clinical trials are discussed.

Citing Articles

Evaluation of maSSS/maSES-PEG2-RM26 for their potential therapeutic use after labeling with Re-188. Could their [Tc]Tc-labeled counterparts be used to estimate dosimetry?.

Kanellopoulos P, Yu Q, Abouzayed A, Bezverkhniaia E, Tolmachev V, Orlova A EJNMMI Radiopharm Chem. 2025; 10(1):3.

PMID: 39825204 PMC: 11748620. DOI: 10.1186/s41181-024-00326-3.

Lead-it-EAZY! GMP-compliant production of [Pb]Pb-PSC-PEG-TOC.

Pretze M, Michler E, Kastner D, Kunkel F, Sagastume E, Schultz M EJNMMI Radiopharm Chem. 2024; 9(1):81.

PMID: 39604560 PMC: 11602913. DOI: 10.1186/s41181-024-00305-8.

Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology.

Tomiyoshi K, Wilson L, Mourtada F, Mourtada J, Namiki Y, Kamata W Pharmaceutics. 2024; 16(11).

PMID: 39598580 PMC: 11597032. DOI: 10.3390/pharmaceutics16111458.

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies.

Alshehri A Diagnostics (Basel). 2024; 14(21).

PMID: 39518374 PMC: 11544963. DOI: 10.3390/diagnostics14212407.

Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.

Vanermen M, Ligeour M, Oliveira M, Gestin J, Elvas F, Navarro L EJNMMI Radiopharm Chem. 2024; 9(1):69.

PMID: 39365487 PMC: 11452365. DOI: 10.1186/s41181-024-00298-4.

References

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kulinski R . Dose escalation study of targeted alpha therapy with [Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy. Eur J Nucl Med Mol Imaging. 2021; 48(11):3595-3605. PMC: 8440247. DOI: 10.1007/s00259-021-05350-y. View

Edem P, Fonslet J, Kjaer A, Herth M, Severin G . In Vivo Radionuclide Generators for Diagnostics and Therapy. Bioinorg Chem Appl. 2017; 2016:6148357. PMC: 5183759. DOI: 10.1155/2016/6148357. View

Dos Santos J, Schafer M, Bauder-Wust U, Lehnert W, Leotta K, Morgenstern A . Development and dosimetry of Pb/Pb-labelled PSMA ligands: bringing "the lead" into PSMA-targeted alpha therapy?. Eur J Nucl Med Mol Imaging. 2019; 46(5):1081-1091. PMC: 6451745. DOI: 10.1007/s00259-018-4220-z. View

Li M, Sagastume E, Lee D, McAlister D, DeGraffenreid A, Olewine K . Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer. Curr Med Chem. 2020; 27(41):7003-7031. PMC: 10613023. DOI: 10.2174/0929867327999200727190423. View

Li M, Baumhover N, Liu D, Cagle B, Boschetti F, Paulin G . Preclinical Evaluation of a Lead Specific Chelator (PSC) Conjugated to Radiopeptides for Pb and Pb-Based Theranostics. Pharmaceutics. 2023; 15(2). PMC: 9966725. DOI: 10.3390/pharmaceutics15020414. View

Hammer S, Hagemann U, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S . Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer. Clin Cancer Res. 2019; 26(8):1985-1996. DOI: 10.1158/1078-0432.CCR-19-2268. View

Zacherl M, Gildehaus F, Mittlmeier L, Boning G, Gosewisch A, Wenter V . First Clinical Results for PSMA-Targeted α-Therapy Using Ac-PSMA-I&T in Advanced-mCRPC Patients. J Nucl Med. 2020; 62(5):669-674. DOI: 10.2967/jnumed.120.251017. View

Rajerison H, Faye D, Roumesy A, Louaisil N, Boeda F, Faivre-Chauvet A . Ionic liquid supported organotin reagents to prepare molecular imaging and therapy agents. Org Biomol Chem. 2016; 14(6):2121-6. DOI: 10.1039/c5ob02459e. View

Muller C, Vermeulen C, Koster U, Johnston K, Turler A, Schibli R . Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics. EJNMMI Radiopharm Chem. 2018; 1(1):5. PMC: 5843804. DOI: 10.1186/s41181-016-0008-2. View

10.

Miederer M, McDevitt M, Sgouros G, Kramer K, Cheung N, Scheinberg D . Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004; 45(1):129-37. View

11.

Drecoll E, Gaertner F, Miederer M, Blechert B, Vallon M, Muller J . Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One. 2009; 4(5):e5715. PMC: 2682652. DOI: 10.1371/journal.pone.0005715. View

12.

Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M . Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with Bi-substance P analogue. Eur J Nucl Med Mol Imaging. 2018; 45(9):1636-1644. PMC: 6061489. DOI: 10.1007/s00259-018-4015-2. View

13.

Aneheim E, Gustafsson A, Albertsson P, Back T, Jensen H, Palm S . Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates. Bioconjug Chem. 2016; 27(3):688-97. DOI: 10.1021/acs.bioconjchem.5b00664. View

14.

Dauer L, Williamson M, Humm J, ODonoghue J, Ghani R, Awadallah R . Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer. Health Phys. 2014; 106(4):494-504. PMC: 4981573. DOI: 10.1097/HP.0b013e3182a82b37. View

15.

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

16.

Sgouros G, He B, Ray N, Ludwig D, Frey E . Dosimetric impact of Ac-227 in accelerator-produced Ac-225 for alpha-emitter radiopharmaceutical therapy of patients with hematological malignancies: a pharmacokinetic modeling analysis. EJNMMI Phys. 2021; 8(1):60. PMC: 8374020. DOI: 10.1186/s40658-021-00410-6. View

17.

Kratochwil C, Giesel F, Bruchertseifer F, Mier W, Apostolidis C, Boll R . ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014; 41(11):2106-19. PMC: 4525192. DOI: 10.1007/s00259-014-2857-9. View

18.

McDevitt M, Ma D, Lai L, Simon J, Borchardt P, Frank R . Tumor therapy with targeted atomic nanogenerators. Science. 2001; 294(5546):1537-40. DOI: 10.1126/science.1064126. View

19.

Rubira L, Deshayes E, Santoro L, Kotzki P, Fersing C . Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic. Pharmaceutics. 2023; 15(4). PMC: 10146019. DOI: 10.3390/pharmaceutics15041051. View

20.

Yadav M, Ballal S, Sahoo R, Bal C . Efficacy and safety of Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur J Nucl Med Mol Imaging. 2021; 49(5):1595-1606. PMC: 8626283. DOI: 10.1007/s00259-021-05632-5. View